RT Journal Article
SR Electronic
T1 Protective characteristics of COVID-19 convalescent and post-vaccination IgG antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.19.21266547
DO 10.1101/2021.11.19.21266547
A1 Klegerman, Melvin E.
A1 Peng, Tao
A1 Seferovich, Ira
A1 Rahbar, Mohammad H.
A1 Hessabi, Manouchehr
A1 Tahanan, Amirali
A1 Wanger, Audrey
A1 Grimes, Carolyn Z.
A1 Ostrosky-Zeichner, Luis Z.
A1 Koster, Kent
A1 Cirillo, Jeffrey D.
A1 Abeydeera, Dinuka
A1 De Lira, Steve
A1 McPherson, David D.
YR 2021
UL http://medrxiv.org/content/early/2021/11/21/2021.11.19.21266547.abstract
AB Soon after commencement of the SARS-CoV-2 disease outbreak of 2019 (COVID-19), it became evident that the receptor-binding domain of the viral spike protein is the target of neutralizing antibodies that comprise a critical element of protective immunity to the virus. This study addresses the relative lack of information regarding actual antibody concentrations in convalescent plasma samples from COVID-19 patients and extends these analyses to post-vaccination samples to estimate protective IgG antibody (Ab) levels. Both sample populations were similar and a protective Ab level of 7.5 µg/ml was determined, based on 95% of the normal distribution of the post-vaccination population. The results of this study have implications for future vaccine development, projection of protective efficacy duration, and understanding of the immune response to SARS-CoV-2 infection.One-Sentence Summary Using two quantitative immunoassays, we have found similar IgG antibody responses to the SARS-CoV-2 spike protein in populations of COVID-19 survivors and vaccine recipients that indicate a protective antibody concentration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTexas A&M University System, BADAS Study (Bacillus Calmette-Guérin Vaccination as defense against SARS-CoV-2. A Randomized Placebo-Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses) (MEK, JDC, KK) Biostatistics/ Epidemiology/Research Design (BERD) component of the Center for Clinical and Translational Sciences (CCTS), mainly funded by a grant (UL1 TR003167) from the National Center for Advancing Translational Sciences (NCATS), awarded to The University of Texas Health Science Center at Houston (UTHealth) (MHR, MH, AT) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Texas Health Science Center Committee for the Protection of Human Subjects approved by expedited review and approval on June 24, 2020. IRB Approval No. HSC-MS-20-0606I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSmall quantities of plasma samples are available to researchers for purposes of reproducing or extending the analysis, subject to materials transfer agreements. Raw data not included in the supplementary materials are available by individual arrangement.